ArticleMaedica2025
Caspase 3/8/9 Apoptotic Pathway Deregulation Analysis in Laryngeal Squamous Cell Carcinoma.
Article in Maedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Among the molecules that are implicated in the regulation of apoptosis (programmed cell death), caspases are most significant acting as strong enhancers. The aim of the current study was to co-analyze the caspases 3, 8 and 9 at their protein expression level in a series of laryngeal squamous cell carcinomas (LSCCs). Materials and methods: Tissue specimens derived from 50 LSCC cases were selected and co-analyzed for determining the caspase 3/8/9 expression. A combination of immunohistochemistry and digital image analysis assays was implemented. Results: According to the analysis of the immunostained slides, females showed higher median expression levels of caspase 3/9 and lower caspase 8 compared to males. However, none of these differences reached statistical significance. Furthermore, median caspase 3 expression levels decreased from Grade 1 to Grade 3, and similar gradual changes were noted for other markers. However, none of these differences reached statistical significance, indicating that the distributions of the biomarkers did not differ significantly by grade. Interestingly, the median caspase 3 levels strongly decreased with stage and this difference was significant (p = 0.033). No significant differences were found across stages for caspase 8/9 and also regarding the anatomical region of the examined tumors. Conclusion: Deregulation of caspase 3/8/9 molecules that regulate a crucial cataract of reactions in the apoptotic pathway is a relatively frequent event in LSCCs. Progressive loss of their expression is correlated with an aggressive phenotype in the corresponding malignancies, especially referring to caspase 3. Enhancing caspase 3/8/9 expression - that induces apoptotic rates in malignant tumors including LSCC - is a significant goal and challenge for developing novel targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.